Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (766)	12/17/1999 10:10:00 PM
From: blankmind	Read Replies (1) \| Respond to of 10345

Business This Week 1 (News Digest): Alzheimer's clinical studies Irish Times, 12/17/1999, 81 words. Elan Corporation has initiated phase-one clinical studies with Betabloc, its new therapeutic agent, for use in the treatment of Alzheimer's disease. Used in animal studies, Betabloc prevented the ... Elan hopes to break the mold The News & Observer Raleigh, NC, 12/17/1999, 546 words. Guadalajara, Mexico. It's not the first place mainstream American record scouts might look for the next English-language female folk-pop star. After all, ... Targeted Genetics Initiates Clinical Trial in Ovarian Cancer - Phase I ... PR Newswire, 12/16/1999, 1200 words. SEATTLE, Wash., Dec. 16 /PRNewswire/ -- Targeted Genetics Corp. (Nasdaq: TGEN) today announced that the Company has initiated a Phase I clinical trial of tgDCC-E1A for the treatment of ovarian cancer. The study will enroll up to ... Sheffield Pharmaceuticals Successfully Completes Study for Pulmonary ... PR Newswire, 12/16/1999, 583 words. ST. LOUIS, Dec. 16 /PRNewswire/ -- Sheffield Pharmaceuticals, Inc. (Amex: SHM) today announced the successful completion of a pilot study using Sheffield's Aerosol Drug Delivery System (ADDS) to deliver ergotamine, an ... Elan's Betabloc Enters Clinical Studies for Treatment of Alzheimer's PR Newswire, 12/16/1999, 363 words. DUBLIN, Ireland, Dec. 16 /PRNewswire/ -- Elan Corporation, plc (NYSE: ELN) ("Elan") today announced that it has initiated Phase I clinical studies with Betabloc (AN 1792), its new therapeutic agent intended for the treatment of ... UK: GINS-GLOBAL INSURANCE NEWS SUMMARY-DECEMBER 16. Reuters English News Service, 12/16/1999, 2873 words. * * * GINS * * * Global Insurance News Summary Irish Elan Says Alzheimer Drug Starts Clinical Studies Dow Jones International News, 12/16/1999, 239 words. DUBLIN -(Dow Jones)- Irish-based international pharmaceuticals maker Elan Corp. PLC (ELN) said Thursday that it has started Phase I clinical studies with Betabloc, a therapeutic agent for treating Alzheimer's ... Elan Corporation PLC - Re Clinical Studies Regulatory News Service, 12/16/1999, 408 words. ELAN CORPORATION PLC Elan's Betabloc Enters Clinical Studies for Treatment of Alzheimer's Disease